Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01687101 · ClinicalTrials.gov registry record · NA

STOPAIN in the Treatment of a Single Migraine Attack

A NA study of Migraine and Headache, sponsored by Thomas Jefferson University.

Completed
Registry status
NA
Development phase
32
Enrollment target
1
Study location

NCT01687101 is a NA study of Migraine and Headache that has completed, run by Thomas Jefferson University. The registered enrollment target is 32 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01687101, a NA study of Migraine and Headache, has completed, sponsored by Thomas Jefferson University.

COMPLETED
Registry status
NA
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

This is an open label pilot study of 25 subjects with a diagnosis of episodic migraine with or without aura. STOPAIN is an over-the-counter product that is used for the temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises and sprains. We plan to have subjects apply the product during a single migraine attack to see if it will alleviate the headache pain and associated symptoms.

Conditions Studied

Interventions

  • DRUG STOPAIN topical gel

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2012-05
Est. Completion 2013-05
Phase NA

Sponsor

Thomas Jefferson University

292 total trials

What the Registry Record Tells You About NCT01687101

The ClinicalTrials.gov registry entry for NCT01687101 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (91% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which STOPAIN topical gel is the first listed.

NCT01687101 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01687101 about?

NCT01687101 is a clinical study titled "STOPAIN in the Treatment of a Single Migraine Attack". This is an open label pilot study of 25 subjects with a diagnosis of episodic migraine with or without aura. STOPAIN is an over-the-counter product that is used for the temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises and sp...

What is the current status of trial NCT01687101?

This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2012-05. Estimated completion is 2013-05.

What conditions does trial NCT01687101 study?

This clinical trial studies the following conditions: Migraine, Headache.

What interventions are being tested in trial NCT01687101?

The interventions under investigation include: STOPAIN topical gel (DRUG).

Who is sponsoring clinical trial NCT01687101?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01687101 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.